Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM85330 (CAS_68647 | NSC_68647 | ONDANSETRON | Ondansetron ...) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | Purchase DrugBank MCE KEGG PC cid PC sid PDB UniChem Similars | DrugBank PDB Article PubMed | n/a | n/a | 0.0900 | n/a | n/a | n/a | n/a | n/a | n/a |
H. Lundbeck A/S Curated by ChEMBL | Assay Description Antagonist activity at human 5HT3A receptor expressed in xenopus oocytes assessed as inhibition of 5HT-induced effect by electrophysiological method | J Med Chem 54: 3206-21 (2011) Article DOI: 10.1021/jm101459g BindingDB Entry DOI: 10.7270/Q2W37XFC | |||||||||||
More data for this Ligand-Target Pair | 3D Structure (crystal) | ||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221600 (US9303045, 87 | US9695195, 87) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.180 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9695195 (2017) BindingDB Entry DOI: 10.7270/Q28050RV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221600 (US9303045, 87 | US9695195, 87) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.180 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221544 (US9303045, 30 | US9695195, 30) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221544 (US9303045, 30 | US9695195, 30) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9695195 (2017) BindingDB Entry DOI: 10.7270/Q28050RV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221592 (US9303045, 127 | US9303045, 79 | US9695195, 127) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.220 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221592 (US9303045, 127 | US9303045, 79 | US9695195, 127) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.220 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9695195 (2017) BindingDB Entry DOI: 10.7270/Q28050RV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221601 (US9303045, 88 | US9695195, 88) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.220 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9695195 (2017) BindingDB Entry DOI: 10.7270/Q28050RV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221601 (US9303045, 88 | US9695195, 88) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.220 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221622 (US9303045, 113 | US9695195, 113) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.230 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9695195 (2017) BindingDB Entry DOI: 10.7270/Q28050RV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221622 (US9303045, 113 | US9695195, 113) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.230 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221572 (US9303045, 58 | US9695195, 58) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.240 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221572 (US9303045, 58 | US9695195, 58) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.240 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9695195 (2017) BindingDB Entry DOI: 10.7270/Q28050RV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221624 (US9303045, 117 | US9303045, 123 | US9695195, 123) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.280 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9695195 (2017) BindingDB Entry DOI: 10.7270/Q28050RV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221624 (US9303045, 117 | US9303045, 123 | US9695195, 123) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.280 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221610 (US9303045, 99 | US9695195, 99) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.290 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221610 (US9303045, 99 | US9695195, 99) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.290 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9695195 (2017) BindingDB Entry DOI: 10.7270/Q28050RV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221654 (US9303045, 159 | US9695195, 159) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.298 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221654 (US9303045, 159 | US9695195, 159) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.300 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9695195 (2017) BindingDB Entry DOI: 10.7270/Q28050RV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221651 (US9303045, 154 | US9695195, 154) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.328 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221561 (US9303045, 47 | US9695195, 47) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.330 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9695195 (2017) BindingDB Entry DOI: 10.7270/Q28050RV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221561 (US9303045, 47 | US9695195, 47) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.330 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221651 (US9303045, 154 | US9695195, 154) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.330 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9695195 (2017) BindingDB Entry DOI: 10.7270/Q28050RV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221627 (US9303045, 120 | US9695195, 120) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.390 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9695195 (2017) BindingDB Entry DOI: 10.7270/Q28050RV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221627 (US9303045, 120 | US9695195, 120) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.390 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221624 (US9303045, 117 | US9303045, 123 | US9695195, 123) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.390 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9695195 (2017) BindingDB Entry DOI: 10.7270/Q28050RV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221624 (US9303045, 117 | US9303045, 123 | US9695195, 123) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.390 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221626 (US9303045, 119 | US9695195, 148) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.400 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9695195 (2017) BindingDB Entry DOI: 10.7270/Q28050RV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221622 (US9303045, 113 | US9695195, 113) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.400 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9695195 (2017) BindingDB Entry DOI: 10.7270/Q28050RV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221535 (US9303045, 20 | US9695195, 20) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.400 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9695195 (2017) BindingDB Entry DOI: 10.7270/Q28050RV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221626 (US9303045, 119 | US9695195, 148) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.400 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9695195 (2017) BindingDB Entry DOI: 10.7270/Q28050RV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221648 (US9303045, 147 | US9695195, 147) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.400 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9695195 (2017) BindingDB Entry DOI: 10.7270/Q28050RV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221648 (US9303045, 147 | US9695195, 147) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.400 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221679 (US9303045, 21) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.400 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221626 (US9303045, 119 | US9695195, 148) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.400 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221535 (US9303045, 20 | US9695195, 20) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.400 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221649 (US9303045, 148) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.400 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221592 (US9303045, 127 | US9303045, 79 | US9695195, 127) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.410 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9695195 (2017) BindingDB Entry DOI: 10.7270/Q28050RV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221592 (US9303045, 127 | US9303045, 79 | US9695195, 127) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.410 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221644 (US9303045, 143 | US9695195, 143) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.415 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221587 (US9303045, 74 | US9695195, 74) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.420 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9695195 (2017) BindingDB Entry DOI: 10.7270/Q28050RV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221587 (US9303045, 74 | US9695195, 74) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.420 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221644 (US9303045, 143 | US9695195, 143) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.420 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9695195 (2017) BindingDB Entry DOI: 10.7270/Q28050RV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221574 (US9303045, 60 | US9695195, 60) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.440 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9695195 (2017) BindingDB Entry DOI: 10.7270/Q28050RV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221574 (US9303045, 60 | US9695195, 60) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.440 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221527 (US9303045, 12 | US9695195, 12) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.450 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9695195 (2017) BindingDB Entry DOI: 10.7270/Q28050RV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221527 (US9303045, 12 | US9695195, 12) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.450 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221677 (US9303045, 189 | US9695195, 189) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.460 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9695195 (2017) BindingDB Entry DOI: 10.7270/Q28050RV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM221677 (US9303045, 189 | US9695195, 189) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.460 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a... | US Patent US9303045 (2016) BindingDB Entry DOI: 10.7270/Q2NZ86HD | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
5-hydroxytryptamine receptor 3A (Homo sapiens (Human)) | BDBM233390 (US9346829, 29) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.462 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Phamaceutical Company Limited US Patent | Assay Description The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ... | US Patent US9346829 (2016) BindingDB Entry DOI: 10.7270/Q2MK6BRB | |||||||||||
More data for this Ligand-Target Pair |
Displayed 1 to 50 (of 796 total ) | Next | Last >> |